0000950170-24-040478.txt : 20240402 0000950170-24-040478.hdr.sgml : 20240402 20240402181042 ACCESSION NUMBER: 0000950170-24-040478 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240325 FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Garner Charles CENTRAL INDEX KEY: 0001602444 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 24816084 MAIL ADDRESS: STREET 1: 490 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aileron Therapeutics, Inc. CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 134196017 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12407 N. MOPAC EXPY. STREET 2: SUITE 250 #390 CITY: AUSTIN STATE: TX ZIP: 78758 BUSINESS PHONE: 7378021989 MAIL ADDRESS: STREET 1: 12407 N. MOPAC EXPY. STREET 2: SUITE 250 #390 CITY: AUSTIN STATE: TX ZIP: 78758 FORMER COMPANY: FORMER CONFORMED NAME: AILERON THERAPEUTICS INC DATE OF NAME CHANGE: 20071207 3 1 ownership.xml 3 X0206 3 2024-03-25 0 0001420565 Aileron Therapeutics, Inc. ALRN 0001602444 Garner Charles C/O AILERON THERAPEUTICS, INC. 12407 N. MOPAC EXPY, SUITE 250 #390 AUSTIN TX 78758 false true false false Senior Vice President, Finance Stock Option (right to buy) 1.17 2030-03-31 Common Stock 349750 D Stock Option (right to buy) 2.34 2033-02-09 Common Stock 25597 D On October 31, 2023, the Issuer completed its merger with Lung Therapeutics, Inc. (the "Merger") in accordance with the terms of the Agreement and Plan of Merger, dated October 31, 2023. In connection with the Merger, the Issuer assumed the Reporting Person's option to purchase 2,049,557 shares of Lung Therapeutics, Inc. common stock originally granted on April 1, 2020, which option was converted into an option to purchase 349,750 shares of Issuer common stock. The shares underlying the options are fully vested. In connection with the Merger, the Issuer assumed the Reporting Person's option to purchase 150,000 shares of Lung Therapeutics, Inc. common stock originally granted on February 10, 2023, which option was converted into an option to purchase 25,597 shares of Issuer common stock. 25% of the shares underlying the option vested on the first anniversary of the grant date, and, thereafter, the remaining 75% of such shares vest in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service with the Issuer on each applicable vesting date. /s/ Charles T. Garner 2024-04-02